Literature DB >> 22450225

Immunological modulation by 1α,25-dihydroxyvitamin D3 in patients with squamous cell carcinoma of the head and neck.

David D Walker1, Travis D Reeves, Anna-Maria de Costa, Corinne Schuyler, M Rita I Young.   

Abstract

Prior studies showing that treatment of head and neck squamous cell carcinoma (HNSCC) patients with 1α,25-dihydroxyvitamin D(3) [1,25(OH)(2)D(3)] stimulated intratumoral immune infiltration were extended to analysis of cytokine profiles in the periphery and in oral tissues. Most prominent was the disparity between cytokine levels in plasma and in either pathologically normal oral tissue or HNSCC tissue from patients that were untreated or treated with 1,25(OH)(2)D(3). Levels of IL-6 and IL-10, but not IL-2, IFN-γ or TNF-α, tended to be increased in the plasma of HNSCC patients and 1,25(OH)(2)D(3) further increased plasma levels of all of these cytokines. While these cytokines tended to be increased in HNSCC tissue, 1,25(OH)(2)D(3) resulted in variable cytokine responses that showed a general tendency toward further increased levels. Levels of IL-8 and VEGF were increased in plasma and tissue of untreated HNSCC patients, and were further increased in plasma, but not in tissues, of patients treated with 1,25(OH)(2)D(3). Levels of IL-1α and IL-1β were similar in plasma of controls and HNSCC patients, but were increased in HNSCC tissues. In contrast to that seen in plasma where 1,25(OH)(2)D(3) increased levels of IL-1α and IL-1β, this was not seen in tissue following 1,25(OH)(2)D(3) treatment. These results show a discordant relationship between systemic and intratumoral cytokine profiles and suggest a tendency of 1,25(OH)(2)D(3)to increase a multitude of cytokines within tumor tissue. Published by Elsevier Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22450225      PMCID: PMC3340440          DOI: 10.1016/j.cyto.2012.03.002

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  28 in total

Review 1.  Transcriptional regulation of Th1/Th2 polarization.

Authors:  J Rengarajan; S J Szabo; L H Glimcher
Journal:  Immunol Today       Date:  2000-10

2.  Effect of 1,25 dihydroxyvitamin D3 on intracellular IFN-gamma and TNF-alpha positive T cell subsets in pulmonary tuberculosis.

Authors:  S Prabhu Anand; P Selvaraj; P R Narayanan
Journal:  Cytokine       Date:  2008-12-16       Impact factor: 3.861

3.  Vitamin D3 treatment to diminish the levels of immune suppressive CD34+ cells increases the effectiveness of adoptive immunotherapy.

Authors:  K M Wiers; D M Lathers; M A Wright; M R Young
Journal:  J Immunother       Date:  2000-01       Impact factor: 4.456

4.  IL (interleukin)-1alpha promotes nuclear factor-kappaB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas.

Authors:  J S Wolf; Z Chen; G Dong; J B Sunwoo; C C Bancroft; D E Capo; N T Yeh; N Mukaida; C Van Waes
Journal:  Clin Cancer Res       Date:  2001-06       Impact factor: 12.531

5.  Analysis of Th1 and Th2 cytokine production by peripheral blood mononuclear cells as a parameter of immunological dysfunction in advanced cancer patients.

Authors:  S Goto; M Sato; R Kaneko; M Itoh; S Sato; S Takeuchi
Journal:  Cancer Immunol Immunother       Date:  1999-11       Impact factor: 6.968

6.  Recurrence at the primary site in head and neck cancer and the significance of neck lymph node metastases as a prognostic factor.

Authors:  C R Leemans; R Tiwari; J J Nauta; I van der Waal; G B Snow
Journal:  Cancer       Date:  1994-01-01       Impact factor: 6.860

Review 7.  Trials and tribulations of immunotherapy as a treatment option for patients with squamous cell carcinoma of the head and neck.

Authors:  M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2003-11-22       Impact factor: 6.968

8.  Pharmacokinetics of high-dose oral calcitriol: results from a phase 1 trial of calcitriol and paclitaxel.

Authors:  Josephia R Muindi; Yibing Peng; Douglas M Potter; Pamela A Hershberger; Jil S Tauch; Mary Jo Capozzoli; Merrill J Egorin; Candace S Johnson; Donald L Trump
Journal:  Clin Pharmacol Ther       Date:  2002-12       Impact factor: 6.875

9.  Second primary tumors in patients with head and neck squamous cell carcinoma.

Authors:  A S Jones; P Morar; D E Phillips; J K Field; D Husband; T R Helliwell
Journal:  Cancer       Date:  1995-03-15       Impact factor: 6.860

10.  Phase 1B study to improve immune responses in head and neck cancer patients using escalating doses of 25-hydroxyvitamin D3.

Authors:  Deanne M R Lathers; Joseph I Clark; Nicholas J Achille; M Rita I Young
Journal:  Cancer Immunol Immunother       Date:  2003-11-26       Impact factor: 6.968

View more
  10 in total

Review 1.  Hampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancer.

Authors:  Sabrin Husein Albeituni; Chuanlin Ding; Jun Yan
Journal:  Cancer J       Date:  2013 Nov-Dec       Impact factor: 3.360

2.  Impact of dietary vitamin D on initiation and progression of oral cancer.

Authors:  Aparajita Verma; Vui King Vincent-Chong; Hendrik DeJong; Pamela A Hershberger; Mukund Seshadri
Journal:  J Steroid Biochem Mol Biol       Date:  2020-01-22       Impact factor: 4.292

3.  1α,25-dihydroxyvitamin D3 modulates CYP2R1 gene expression in human oral squamous cell carcinoma tumor cells.

Authors:  Kumaran Sundaram; Yuvaraj Sambandam; Eichi Tsuruga; Carol L Wagner; Sakamuri V Reddy
Journal:  Horm Cancer       Date:  2014-02-05       Impact factor: 3.869

4.  Vitamin D deficiency in head and neck cancer patients - prevalence, prognostic value and impact on immune function.

Authors:  Florian Bochen; Benedikt Balensiefer; Sandrina Körner; Jörg Thomas Bittenbring; Frank Neumann; Armand Koch; Klaus Bumm; Anke Marx; Silke Wemmert; Georgios Papaspyrou; David Zuschlag; Jan Philipp Kühn; Basel Al Kadah; Bernhard Schick; Maximilian Linxweiler
Journal:  Oncoimmunology       Date:  2018-07-23       Impact factor: 8.110

5.  Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1α,25-Dihydroxyvitamin D3 Treatment upon Cancer Diagnosis.

Authors:  M Rita I Young; Corinne Levingston; Sara D Johnson
Journal:  Cancers (Basel)       Date:  2015-06-25       Impact factor: 6.639

6.  An Inflammatory Cytokine Milieu is Prominent in Premalignant Oral Lesions, but Subsides when Lesions Progress to Squamous Cell Carcinoma.

Authors:  Danielle Woodford; Sara D Johnson; Anna-Maria A De Costa; M Rita I Young
Journal:  J Clin Cell Immunol       Date:  2014-06

7.  Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies.

Authors:  Corinne A Levingston; M Rita I Young
Journal:  Int J Cancer       Date:  2017-01-24       Impact factor: 7.396

Review 8.  The role of vitamin D in head and neck cancer.

Authors:  Said Izreig; Michael Hajek; Heather A Edwards; Saral Mehra; Clarence Sasaki; Benjamin L Judson; Rahmatullah W Rahmati
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-11-03

9.  Hypovitaminosis D, oral potentially malignant disorders, and oral squamous cell carcinoma: a systematic review.

Authors:  A Maturana-Ramírez; J Aitken-Saavedra; A-L Guevara-Benítez; I Espinoza-Santander
Journal:  Med Oral Patol Oral Cir Bucal       Date:  2022-03-01

Review 10.  Vitamin D in Head and Neck Cancer: a Systematic Review.

Authors:  Antti Mäkitie; Iida Tuokkola; Göran Laurell; Outi Mäkitie; Kerry Olsen; Robert P Takes; Ewa Florek; Krzysztof Szyfter; Cornelis F M Sier; Alfio Ferlito
Journal:  Curr Oncol Rep       Date:  2020-11-20       Impact factor: 5.075

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.